Publikationen 2003
1: Huland E, Burger A, Fleischer J, Fornara P, Hatzmann E, Heidenreich A,
Heinzer H, Heynemann H, Hoffmann L, Hofmann R, Huland H, Kampfer I, Kindler M,
Kirchner H, Mehlhorn G, Moniak TH, Rebmann U, Roigas J, Schneider TH, Schnorr D,
Schmitz HJ, Wenisch R, Varga Z, Vinke J.
Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal
cell cancer patients compared with systemic interleukin-2: an outcome study.
Folia Biol (Praha). 2003;49(5):183-90.
2: Haese A, Graefen M, Steuber T, Becker C, Noldus J, Erbersdobler A, Huland
E, Huland H, Lilja H.
Total and Gleason grade 4/5 cancer volumes are major contributors of human
kallikrein 2, whereas free prostate specific antigen is largely contributed by
benign gland volume in serum from patients with prostate cancer or benign
prostatic biopsies.
J Urol. 2003 Dec;170(6 Pt 1):2269-73.
3: Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J,
Huland H.
Comparison of multitarget fluorescence in situ hybridization in urine with
other noninvasive tests for detecting bladder cancer.
BJU Int. 2003 Dec;92(9):911-4.
4: Heinzer H, Huland E, Huland H.
Immunotherapy of renal cell carcinoma. With special emphasis on therapy of the
elderly patient
Urologe A. 2003 Nov;42(11):1450-2. German.
5: Graefen M, Huland H.
Prostate carcinoma: many developments in diagnosis and treatment
Urologe A. 2003 Sep;42(9):1170-1. German.
6: Noldus J, Huland H.
Treatment of localized prostate cancer
Onkologie. 2003 Oct;26 Suppl 4:6-12. German.
7: Aalamian M, Tourkova IL, Chatta GS, Lilja H, Huland E, Huland H, Shurin GV,
Shurin MR.
Inhibition of dendropoiesis by tumor derived and purified prostate specific
antigen.
J Urol. 2003 Nov;170(5):2026-30.
8: Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C,
Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E,
Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG,
Scardino PT, Kattan MW.
A preoperative nomogram identifying decreased risk of positive pelvic lymph
nodes in patients with prostate cancer.
J Urol. 2003 Nov;170(5):1798-803.
9: Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A,
Graefen M, Huland H, Koh H, Shariat SF, Slawin KM, Ohori M.
Counseling men with prostate cancer: a nomogram for predicting the presence of
small, moderately differentiated, confined tumors.
J Urol. 2003 Nov;170(5):1792-7.
10: Augustin H, Hammerer PG, Graefen M, Palisaar J, Daghofer F, Huland H,
Erbersdobler A.
Characterisation of biomolecular profiles in primary high-grade prostate cancer
treated by radical prostatectomy.
J Cancer Res Clin Oncol. 2003 Nov;129(11):662-8. Epub 2003 Sep 26.
11: Graefen M, Hammerer PG, Haese A, Huland H.
Indications for and results of radical prostatectomy
Urologe A. 2003 Sep;42(9):1203-11. Review. German.
12: Michl U, Graefen M, Noldus J, Eggert T, Huland H.
Functional results of various surgical techniques for radical prostatectomy
Urologe A. 2003 Sep;42(9):1196-202. Review. German.
13: Palisaar J, Eggert T, Graefen M, Haese A, Huland H.
Transrectal ultrasound-guided punch biopsies of the prostate. Indication,
technique, results, and complications
Urologe A. 2003 Sep;42(9):1188-95. Review. German.
14: Haese A, Graefen M, Palisaar J, Huland E, Huland H.
[Serum markers for early detection and staging of prostate cancer. Status
report on current and future markers]
Urologe A. 2003 Sep;42(9):1172-87. Review. German.
PMID: 14504750 [PubMed - indexed for MEDLINE]
15: Friedrich MG, Toma MI, Petri S, Huland H.
Cyclooxygenase-2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma
but does not predict recurrence.
BJU Int. 2003 Sep;92(4):389-92.
16: Augustin H, Graefen M, Palisaar J, Blonski J, Erbersdobler A, Daghofer F,
Huland H, Hammerer PG.
Prognostic significance of visible lesions on transrectal ultrasound in
impalpable prostate cancers: implications for staging.
J Clin Oncol. 2003 Aug 1;21(15):2860-8.
17: Haese A, Khan MA, Sokoll LJ.
Total, free and complexed PSA and hK2 for early detection of prostate cancer.
MLO Med Lab Obs. 2003 Jun;35(6):14-6, 20, 22 passim; quiz 30-1. No abstract
available.
18: Augustin H, Hammerer PG, Blonski J, Graefen M, Palisaar J, Daghofer F,
Huland H, Erbersdobler A.
Zonal location of prostate cancer: significance for disease-free survival after
radical prostatectomy?
Urology. 2003 Jul;62(1):79-85.
19: Aleman M, Karakiewicz PI, Kupelian P, Kattan MW, Graefen M, Cagiannos I,
Eastham J, Scardino PT, Huland H, Klein EA.
Age and PSA predict likelihood of organ-confined disease in men presenting with
PSA less than 10 ng/mL: implications for screening.
Urology. 2003 Jul;62(1):70-4.
20: Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J,
Fernandez S, Noldus J, Erbersdobler A, Cagiannos I, Scardino PT, Kattan MW,
Huland H.
Can nomograms derived in the U.S. applied to German patients? A study about
the validation of preoperative nomograms predicting the risk of recurrence after
radical prostatectomy
Urologe A. 2003 May;42(5):685-92. Epub 2003 Jan 17. German.
21: Friedrich MG, Hellstern A, Hautmann SH, Noldus I, Huland H.
[Non-invasive urine tests in diagnosis and as prognostic markers for urinary
bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with
immunocytology using monoclonal antibodies against Lewis X and 486p3/12]
Urologe A. 2003 Apr;42(4):523-30.
22: Augustin H, Hammerer PG, Graefen M, Erbersdobler A, Blonski J, Palisaar J,
Daghofer F, Huland H.
Insignificant prostate cancer in radical prostatectomy specimen: time trends
and preoperative prediction.
Eur Urol. 2003 May;43(5):455-60.
23: Augustin H, Erbersdobler A, Graefen M, Jaekel T, Haese A, Huland H,
Hammerer PG.
Differences in biopsy features between prostate cancers located in the
transition and peripheral zone.
BJU Int. 2003 Apr;91(6):477-81.
24: Haese A, Vaisanen V, Finlay JA, Pettersson K, Rittenhouse HG, Partin AW,
Bruzek DJ, Sokoll LJ, Lilja H, Chan DW.
Standardization of two immunoassays for human glandular kallikrein 2.
Clin Chem. 2003 Apr;49(4):601-10.
25: Augustin H, Erbersdobler A, Graefen M, Fernandez S, Palisaar J, Huland H,
Hammerer P.
Biochemical recurrence following radical prostatectomy: a comparison between
prostate cancers located in different anatomical zones.
Prostate. 2003 Apr 1;55(1):48-54.
26: Haese A, Chaudhari M, Miller MC, Epstein JI, Huland H, Palisaar J, Graefen
M, Hammerer P, Poole EC, O'Dowd GJ, Partin AW, Veltri RW.
Quantitative biopsy pathology for the prediction of pathologically
organ-confined prostate carcinoma: a multiinstitutional validation study.
Cancer. 2003 Feb 15;97(4):969-78.
27: Friedrich MG, Hellstern A, Toma MI, Hammerer P, Huland H.
Are false-positive urine markers for the detection of bladder carcinoma really
wrong or do they predict tumor recurrence?
Eur Urol. 2003 Feb;43(2):146-50; discussion 150-1.
PMID: 12565772 [PubMed - indexed for MEDLINE]
28: Augustin H, Hammerer P, Graefen M, Palisaar J, Noldus J, Fernandez S,
Huland H.
Intraoperative and perioperative morbidity of contemporary radical retropubic
prostatectomy in a consecutive series of 1243 patients: results of a single
center between 1999 and 2002.
Eur Urol. 2003 Feb;43(2):113-8.
29: Haese A, Graefen M, Becker C, Noldus J, Katz J, Cagiannos I, Kattan M,
Scardino PT, Huland E, Huland H, Lilja H.
The role of human glandular kallikrein 2 for prediction of pathologically organ
confined prostate cancer.
Prostate. 2003 Feb 15;54(3):181-6.
30: Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J,
Blonski J, Fernandez S, Erbersdobler A, Huland H.
Can predictive models for prostate cancer patients derived in the United States
of America be utilized in European patients? A validation study of the Partin
tables.
Eur Urol. 2003 Jan;43(1):6-10; discussion 11.
© Universitätsklinikum Hamburg-Eppendorf,
ImpressumLetzte Änderung:
, 22.01.2005
